β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
Nsengimana J, Laye J, Filia A, O'Shea S, Muralidhar S, Poźniak J, Droop A, Chan M, Walker C, Parkinson L, Gascoyne J, Mell T, Polso M, Jewell R, Randerson-Moor J, Cook GP, Bishop DT, Newton-Bishop J.
J Clin Invest
128 :
2018
2048-2063
59
Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma.
Poźniak J, Nsengimana J, Laye JP, O'Shea SJ, Diaz JMS, Droop AP, Filia A, Harland M, Davies JR, Mell T, Randerson-Moor JA, Muralidhar S, Hogan SA, Freiberger SN, Levesque MP, Cook GP, Bishop DT, Newton-Bishop J.
Cancer Res
79 :
2019
2684-2696
29
MX 2 is a novel regulator of cell cycle in melanoma cells.
Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Øy GF, Trøen G, Flørenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A.
Pigment Cell Melanoma Res
33 :
2020
446-457
9
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.
Kato S, Weng QY, Insco ML, Chen KY, Muralidhar S, Pozniak J, Diaz JMS, Drier Y, Nguyen N, Lo JA, van Rooijen E, Kemeny LV, Zhan Y, Feng Y, Silkworth W, Powell CT, Liau BB, Xiong Y, Jin J, Newton-Bishop J, Zon LI, Bernstein BE, Fisher DE.
Cancer Discov
10 :
2020
980-997
35
PRL3-DDX21 Transcriptional Control of Endolysosomal Genes Restricts Melanocyte Stem Cell Differentiation.
Johansson JA, Marie KL, Lu Y, Brombin A, Santoriello C, Zeng Z, Zich J, Gautier P, von Kriegsheim A, Brunsdon H, Wheeler AP, Dreger M, Houston DR, Dooley CM, Sims AH, Busch-Nentwich EM, Zon LI, Illingworth RS, Patton EE.
Dev Cell
54 :
2020
317-332.e9
26
Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.
Emran AA, Nsengimana J, Punnia-Moorthy G, Schmitz U, Gallagher SJ, Newton-Bishop J, Tiffen JC, Hersey P.
Cancers (Basel)
12 :
2020
E2082
13
Gene co-expression and histone modification signatures are associated with melanoma progression, epithelial-to-mesenchymal transition, and metastasis.
Azevedo H, Pessoa GC, de Luna Vitorino FN, Nsengimana J, Newton-Bishop J, Reis EM, da Cunha JPC, Jasiulionis MG.
Clin Epigenetics
12 :
2020
127
10
MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy.
Juraleviciute M, Nsengimana J, Newton-Bishop J, Hendriks GJ, Slipicevic A.
Cancer Med
10 :
2021
2840-2854
4
Transcriptional signatures underlying dynamic phenotypic switching and novel disease biomarkers in a linear cellular model of melanoma progression.
Pessoa DO, Rius FE, Papaiz DD, Ayub ALP, Morais AS, de Souza CF, da Paixão VF, Setubal JC, Newton-Bishop J, Nsengimana J, Azevedo H, Reis EM, Jasiulionis MG.
Neoplasia
23 :
2021
439-455
4
Loss of Ambra1 promotes melanoma growth and invasion.
Di Leo L, Bodemeyer V, Bosisio FM, Claps G, Carretta M, Rizza S, Faienza F, Frias A, Khan S, Bordi M, Pacheco MP, Di Martino J, Bravo-Cordero JJ, Daniel CJ, Sears RC, Donia M, Madsen DH, Guldberg P, Filomeni G, Sauter T, Robert C, De Zio D, Cecconi F.
Nat Commun
12 :
2021
2550
30
Inherited duplications of PPP2R3B predispose to nevi and melanoma via a C21orf91-driven proliferative phenotype.
Polubothu S, Zecchin D, Al-Olabi L, Lionarons DA, Harland M, Horswell S, Thomas AC, Hunt L, Wlodarchak N, Aguilera P, Brand S, Bryant D, Carrera C, Chen H, Elgar G, Harwood CA, Howell M, Larue L, Loughlin S, MacDonald J, Malvehy J, Barberan SM, da Silva VM, Molina M, Morrogh D, Moulding D, Nsengimana J, Pittman A, Puig-Butillé JA, Parmar K, Sebire NJ, Scherer S, Stadnik P, Stanier P, Tell G, Waelchli R, Zarrei M, Puig S, Bataille V, Xing Y, Healy E, Moore GE, Di WL, Newton-Bishop J, Downward J, Kinsler VA.
Genet Med
23 :
2021
1636-1647
1
SFPQ promotes an oncogenic transcriptomic state in melanoma.
Bi O, Anene CA, Nsengimana J, Shelton M, Roberts W, Newton-Bishop J, Boyne JR.
Oncogene
40 :
2021
5192-5203
18
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation.
Campbell NR, Rao A, Hunter MV, Sznurkowska MK, Briker L, Zhang M, Baron M, Heilmann S, Deforet M, Kenny C, Ferretti LP, Huang TH, Perlee S, Garg M, Nsengimana J, Saini M, Montal E, Tagore M, Newton-Bishop J, Middleton MR, Corrie P, Adams DJ, Rabbie R, Aceto N, Levesque MP, Cornell RA, Yanai I, Xavier JB, White RM.
Dev Cell
56 :
2021
2808-2825.e10
34
Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas.
Güvenç C, Antoranz A, Szumera-Ciećkiewicz A, Teterycz PP, Rutkowski PR, Rawson RV, Scolyer RA, Thompson JF, Newton-Bishop J, Stas M, Boecxstaens V, Bechter O, Vercauteren J, Garmyn M, van den Oord J, Bosisio FM.
Int J Mol Sci
22 :
2021
10568
3
ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation.
Castro MV, Barbero GA, Villanueva MB, Grumolato L, Nsengimana J, Newton-Bishop J, Illescas E, Quezada MJ, Lopez-Bergami P.
J Biomed Sci
28 :
2021
76
8
Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients.
Papaiz DD, Rius FE, Ayub ALP, Origassa CS, Gujar H, Pessoa DO, Reis EM, Nsengimana J, Newton-Bishop J, Mason CE, Weisenberger DJ, Liang G, Jasiulionis MG.
Mol Oncol
16 :
2022
1913-1930
2
Comprehensive Gene Expression Analysis to Identify Differences and Similarities between Sex- and Stage-Stratified Melanoma Samples.
Chrysanthou E, Sehovic E, Ostano P, Chiorino G.
Cells
11 :
2022
1099
2
Genome-wide promoter methylation profiling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival.
Rius FE, Papaiz DD, Azevedo HFZ, Ayub ALP, Pessoa DO, Oliveira TF, Loureiro APM, Andrade F, Fujita A, Reis EM, Mason CE, Jasiulionis MG.
Clin Epigenetics
14 :
2022
68
3
Identifying the Transcriptional Drivers of Metastasis Embedded within Localized Melanoma.
Suresh S, Rabbie R, Garg M, Lumaquin D, Huang TH, Montal E, Ma Y, Cruz NM, Tang X, Nsengimana J, Newton-Bishop J, Hunter MV, Zhu Y, Chen K, de Stanchina E, Adams DJ, White RM.
Cancer Discov
13 :
2023
194-215
5
N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma.
Wang G, Zeng D, Sweren E, Miao Y, Chen R, Chen J, Wang J, Liao W, Hu Z, Kang S, Garza LA.
J Invest Dermatol
143 :
2023
1579-1590.e5
3
Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy.
Wee Y, Wang J, Wilson EC, Rich CP, Rogers A, Tong Z, DeGroot E, Gopal YNV, Davies MA, Ekiz HA, Tay JKH, Stubben C, Boucher KM, Oviedo JM, Fairfax KC, Williams MA, Holmen SL, Wolff RK, Grossmann AH.
Nat Commun
15 :
2024
6613
0